Steward Partners Investment Advisory’s Travere Therapeutics TVTX Stock Holding History

Steward Partners Investment Advisory’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-500	Closed	-$12.5K	–	7403
2021 Q1	$12.5K	Buy	+500	New	+$13.8K	﹤0.01%	2687
2020 Q4	–	Sell	-275	Closed	-$5K	–	2997
2020 Q3	$5K	Hold	275	–	–	﹤0.01%	2389
2020 Q2	$6K	Hold	275	–	–	﹤0.01%	2233
2020 Q1	$4K	Sell	275 -145	-35%	-$2.18K	﹤0.01%	2163
2019 Q4	$5K	Sell	420 -62	-13%	-$792	﹤0.01%	2256
2019 Q3	$5K	Buy	482 +62	+15%	+$1.02K	﹤0.01%	2259
2019 Q2	$8K	Buy	+420	New	+$8.29K	﹤0.01%	2087
2018 Q4	–	Sell	-145	Closed	-$4K	–	2063
2018 Q3	$4K	Hold	145	–	–	﹤0.01%	2226
2018 Q2	$4K	Hold	145	–	–	﹤0.01%	2079
2018 Q1	$3K	Buy	+145	New	+$3.45K	﹤0.01%	1946

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Steward Partners Investment Advisory's TVTX Position: Q2 2021 in Review

Steward Partners Investment Advisory sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 500 shares — an estimated $12.5K sold.

Steward Partners Investment Advisory first reported a position in TVTX in Q1 2018 and held it in 10 quarters. The position peaked at $12.5K in Q1 2021. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

Steward Partners Investment Advisory reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
Steward Partners Investment Advisory sold 500 Travere Therapeutics shares in Q2 2021, an estimated $12.5K.
Steward Partners Investment Advisory first reported a position in Travere Therapeutics in Q1 2018 and held it in 10 quarters.
Steward Partners Investment Advisory's Travere Therapeutics position peaked at $12.5K in Q1 2021.
136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.